GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT01590615
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
- Conditions
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT01585688
- Locations
- 🇺🇸
UMass Memorial Cancer Center of Excellence, Worcester, Massachusetts, United States
🇺🇸MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸IU Health Goshen Center for Cancer Care, Goshen, Indiana, United States
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
- Conditions
- Interventions
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 416
- Registration Number
- NCT01569295
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇬🇧University College London, London, United Kingdom
🇬🇷G. Genimatas Hospital, Athens, Greece
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 153
- Registration Number
- NCT01565850
- Locations
- 🇺🇸
Peter J. Ruane, MD, Inc., Los Angeles, California, United States
🇺🇸North Shore University Hospital / Division of Infectious Diseases, Manhasset, New York, United States
🇺🇸Southwest Infectious Disease Clinical Research Inc, Dallas, Texas, United States
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT01565889
- Locations
- 🇵🇷
Fundacion de Investigacion de Diego, San Juan, Puerto Rico
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
- Conditions
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT01559844
- Locations
- 🇺🇸
UCLA Medical Center-The Pfleger Liver Institute, Los Angeles, California, United States
🇺🇸St. Louis University Hospital, St. Louis, Missouri, United States
🇺🇸Baylor Health Care System, Dallas, Texas, United States
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2014-09-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 442
- Registration Number
- NCT01555164
- Locations
- 🇺🇸
New Phase Research & Development, Knoxville, Tennessee, United States
🇺🇸National Research Institute, Los Angeles, California, United States
🇺🇸Baptist Diabetes Associates, Miami, Florida, United States
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01546597
- Locations
- 🇺🇸
Cetero Research, San Antonio, Texas, United States
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT01546558
- Locations
- 🇺🇸
SeaView Research Inc., Miami, Florida, United States
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 278
- Registration Number
- NCT01542788
- Locations
- 🇺🇸
Anthony Mills MD, Inc., Los Angeles, California, United States
🇺🇸Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States
🇺🇸Henry Ford Health System, Novi, Michigan, United States